Sanofi (SNY) Tops Q2 EPS by EUR0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
July 29, 2020 1:30 AM EDTÂ Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Q2 2020 sales results reflect the strong performance of Dupixent® more than offset by COVID-19 related negative effects on Vaccines, General Medicines and CHC
Net sales were 8,207million, down 4.9% on a reported basis and a decline of 3.4%(2) at CER. Specialty Care sales grew 17.4% driven by strong performance of Dupixent® (+70% to 858 million).Vaccines sales (-6.8%) were affected by global confinements while in Southern Hemisphere demand for flu vaccines was strong.General Medicines sales... More